GSK Pharma reported strong Q3 performance with revenue up 18% and EBITDA rising 34%. Key brands, including Augmentin and ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for ...

Agencies have always strived to build trust with their pharma clients, but that task is becoming more arduous as AI takes center stage.

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

GSK'227 targets B7-H3 ... strengthening its position as the top-selling brand in asthma and COPD. In 2024, increased use of authorized generic versions of Advair and Flovent fully offset the ...

In the 1980s, a predecessor company to GSK launched a treatment for heartburn and acid reflux: ranitidine, under the brand name Zantac. Over the next four decades, Zantac was used by millions of ...